May 24, 2023 07:01 AM EDTUpdated 07:40 AM

PTC cuts gene therapy programs, discloses PhIII fail in Friedreich's ataxia and CFO exit

Amber Tong

PTC Therapeutics disclosed a string of disappointing news late Tuesday, revealing a Phase III flop, a pipeline reorg to cut

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

RFK Jr. ends annual Covid vaccine recommendations for kids, pregnant women

FDA rejects Savara’s rare lung disease drug over limited manufacturing data

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation